Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

This study has been completed.
Information provided by (Responsible Party):
Hemispherx Biopharma Identifier:
First received: May 6, 2002
Last updated: April 16, 2013
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2006
  Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)